 |
Video: What is a Stock Split?
|
 |
KalVista Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. Co. has developed a proprietary portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema. Co.'s primary focus is on developing oral plasma kallikrein inhibitors for HAE. Co. has developed its candidate sebetralstat into clinical development as a potential oral, on-demand therapy for HAE attacks. Co.'s oral product candidate, KVD824 is also being developed for potential prophylactic treatment of HAE. According to our KALV split history records, KalVista Pharmaceuticals has had 1 split. | |
 |

KalVista Pharmaceuticals (KALV) has 1 split in our KALV split history database. The split for KALV took place on November 22, 2016. This was a 1 for 14 reverse split, meaning for each 14 shares of KALV owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 71.4285714285714 share position following the split.
When a company such as KalVista Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the KALV split history from start to finish, an original position size of 1000 shares would have turned into 71.4285714285714 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into KalVista Pharmaceuticals shares, starting with a $10,000 purchase of KALV, presented on a split-history-adjusted basis factoring in the complete KALV split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/10/2015 |
|
End date: |
03/28/2023 |
|
Start price/share: |
$74.06 |
|
End price/share: |
$6.81 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-90.80% |
|
Average Annual Total Return: |
-25.88% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$919.19 |
|
Years: |
7.97 |
|
|
 |
Date |
Ratio |
11/22/2016 | 1 for 14 |
|
 |